Editorial response: Prophylaxis for Pneumocystis carinii pneumonia - An evolving tale of two populations

Clinical Infectious Diseases

Volumn 29, Issue 4, 1999, Pages 784-786

  Gaut, Paula ^b   Daar, Eric S ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

BACTERIAL PNEUMONIA; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0033502810     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520434     Document Type: Editorial

References (21)

1. El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency vires-infected persons. Clin Infect Dis 1999;29:775-83.
2. Torre-Cisneros J, De la Mata M, Pozo JC, et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis 1999;29:771-4.
3. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46:1-46.
4. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonia. N Engl J Med 1977;316:1419-26.
5. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177-88.
6. Bucher HC, Griffith L, Guyatt GH, Opravil M, Meta-analysis of prophylactic treatment against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:104-14.
7. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11.
8. Bozzette SA, Forthal D, Sattler FR, et al. The tolerance of zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. Am J Med 1995;98:177-82.
9. Perez G, Morton R, Sihoi L, et al. A randomized, prospective comparison of twice daily and thrice weekly trimethoprim-sulfamethoxazole as Pneumocystis prophylaxis [abstract no. WB2199]. In: Program and abstracts of the 7th International Conference on AIDS (Florence). Florence: Istituto Superiore di Sanità, 1991.
10. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med 1998;338:853-60.
11. Wynia MK, Ioannidis JPA, Lau J. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates. AIDS 1998;12:1317-25.
12. Furrer H, Egger M, Opravil M, et al, Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999;340:1301-6.
13. Masur H, Kaplan J. Does Pneumocystis carinii prophylaxis stilt need to be lifelong? [editorial]. N Engl J Med 1999;340:1356-7.
14. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999;28:240-6.
15. Arend SM, Van't Wout JW. Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients-as long as the pros outweigh the cons [editorial]. Clin Infect Dis 1999;28:247-9.
16. Jurado R, Garcia-Herola A, Garcia-Lazaro M, Kindelan JM, Villanueva JL, Torre-Cisneros J. Pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clin Infect Dis 1994;19:218-9.
17. Raviglione MC, Dinan WA, Pablos-Mendez A, et al. Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus infected person. Arch Intern Med 1988;148:2683-5.
18. Centers for Disease Control. Fansidar-associated fatal reaction in an HIV-infected man. MMWR Morb Mortal Wkly Rep 1988;37:571-2.
19. Navin TR, Miller KD, Satriale RF, Lobel HO. Adverse reactions associated with pyrimethamine-sulfadoxine prophylaxis for Pneumocystis carinii infections in AIDS [letter]. Lancet 1985;1:1332.
20. Fischl MA, Dickinson GM. Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome [letter]. Ann Intern Med 1986;105:629.
21. Bessesen MT, Miller LA, Cohn DL, Bartlett S, Ellison RT. Administration of pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients with AIDS. Clin Infect Dis 1995;20:730-1.